Roka Bioscience Completes $20M Series C Equity Financing

Roka Bioscience, Inc., a Warren, NJ-based company that focuses on developing and commercializing innovative solutions based on molecular technologies for the industrial markets, has completed a $20m Series C equity financing.

Investors include OrbiMed Advisors, New Enterprise Associates, Inc., TPG Biotech and Gen-Probe Incorporated (NASDAQ: GPRO).
The financing brings the total amount raised by the company to date to $57.2m.

Founded in September 2009 through a spin-off of Gen-Probe’s industrial testing assets and technology, and led by CEO and President Paul Thomas, Roka Bioscience focuses on developing highly accurate molecular assays for food safety testing and other industrial applications.┬áIts nucleic acid tests will be based on proven technologies and instrument platforms with exclusive licensing rights from Gen-Probe.

Eighteen former Gen-Probe employees with expertise in industrial fields joined Roka at the time of the spin-off. Today the company has 75 employees and operates a California office in San Diego.



Join the discussion